Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566245 | 0.93 | USP30 (0.48) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL22671974 | 0.93 | USP30 (0.48) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL22797244 | 0.93 | ALDH1A1 (0.58) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL18291250 | 0.86 | USP30 (0.50) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL29565945 | 0.84 | ALDH1A1 (0.39) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL22672008 | 0.84 | ALDH1A1 (0.39) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL31057316 | 0.84 | PARP1 (0.42) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL23292407 | 0.84 | USP30 (0.53) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL23523331 | 0.84 | NR1H2 (0.45) | USP30ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL23545108 | 0.84 | NR1H2 (0.45) | USP30ALDH1A1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380468-B1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2020-05-20 | — | — | EP | disclosed |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-06-06 | — | — | US | disclosed |
| US-10196382-B2 | bis-Pyridazine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-9938265-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-04-10 | — | — | US | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152254-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196382-B2 | bis-Pyridazine compounds and their use in treating cancer | GLS2, GLS, GLUL | USP30 3331/4885ALDH1A1 249/4885NPC1 4212/4885 |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | GLS2, GLS, GLUL | USP30 3331/4885ALDH1A1 249/4885NPC1 4212/4885 |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | USP30 3301/4885ALDH1A1 236/4885NPC1 4224/4885 |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | USP30 3331/4885ALDH1A1 249/4885NPC1 4212/4885 |
| US-20170152254-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | USP30 3325/4885ALDH1A1 146/4885NPC1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.